HCL Technologies Ltd has signed a deal with Novotech, the largest independent clinical research organisation in Australia, to implement Oracle’s Siebel Clinical Trial Management System (CTMS) over the next few months.
This marks HCL Technologies’ first Australian life sciences customer win, following on the heels of HCL’s significant global growth in this sector through an engagement with pharmaceutical company Merck & Co.
“HCL has an excellent track record working with pharmaceutical companies globally and our partnership with Novotech further fortifies HCL’s life sciences presence in Australia. With more than 2000 professionals servicing the ANZ region and a broad set of global, multi-vendor capabilities HCL will help Novotech to become more agile in today’s competitive environment,” said Virender Aggarwal, executive vice president of APAC & MEA, HCL Technologies.
The Siebel CTMS will support Novotech’s complete spectrum of clinical trial management services across Asia Pacific. In particular Siebel CTMS will:
* Serve as a centralised repository to collect and track relevant information about clinical trials. The system will allow management of clinical trials at different tiers- local, regional and global,
* Offer an aggregate view of clinical trails undertaken by Novotech and provide up to date information to Novotech’s clients on project progress; and
* Provide timely and accurate reports and dashboards to support tactical and strategic decision making.
HCL Technologies will work with Novotech in phases, starting by assessing the company’s current proprietary clinical trial management system and providing a benchmark for where the system should be in terms of scalability and flexibility. HCL will then implement and validate the Siebel CTMS and most importantly provide training to enable Novotech in using the STMS successfully.
The work with Novotech will showcase HCL’s strength in blending project management and system validation and ensuring clear communication and feedback processes between Novotech and HCL.